Full Press Release Details
Creative Medical Technology
Holdings, Inc. Files Patent on AmnioStem
Mediated Immune Reprogramming
Company Discovers Novel Method of
Suppressing Inflammation
Using Combination Autologous Allogeneic
May 24, 2017 - Phoenix, AZ and
San Diego, CA, Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the "Company") announced today the
filing of a patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming
immune cells of the stroke victim.
The patent application teaches
ways of using the Company's patented AmnioStem allogeneic stem cell to educate' immune cells from stroke patients so as
to reduce inflammation associated with stroke. By reducing inflammation, the Company hopes to develop novel means of increasing
efficacy of therapeutic agents in stroke patients.
enthusiastic with our current data, which seems to suggest that AmnioStem cells are not only capable of inducing
regeneration of injured brains, but also can be used to reprogram' immune system cells of patients in order to
reduce inflammation that occurs subsequent to stroke." Said Timothy Warbington, President and CEO of Creative Medical
Technology Holdings. "Working together with immunologists, neurologists, and stem cell experts, we are fortunate to
have a team that can attack the problem of stroke in a multidisciplinary manner."
It is known that the immune system contributes to the deterioration of
brain functions after a stroke. For example, studies in the mouse model of stroke have shown that if certain immune cells are
depleted, the neurological impact of a stroke is diminished.1 It is also known that part of the therapeutic activities
of stem cells in a stroke are mediated by alterations of the immune system.2
are confident that the novel findings presented in the patent application will pave the way for using AmnioStem treated
patient immune cells as a means of suppressing pathological responses, which is applicable not only to stroke but to a wide variety
of neuroinflammatory conditions including multiple sclerosis and traumatic brain injury." Said Thomas lchim, Ph.D., Chief
Scientific Officer of Creative Medical Technology Holdings.
1 Belinga et al. Splenectomy
following MCAO inhibits the TLR4-NF-KB signaling pathway and protects the brain from neurodegeneration in rats. J Neuroimmunol.
2016 Apr 15; 293:105-13
2 Cheng et al. Human umbilical
cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. Brain
Res. 2015 Jan 12;1594:293-304.
https://www .ncbi.nlm.nih.gov/pubmed/?term=25449888
Creative Medical Technology
Holdings, Inc. is a clinical-stage biotechnology company with two focus areas: 1) Personalized stem cell procedures for sexual
dysfunction and infertility; and 2) Universal, off-the-shelf amniotic fluid-based stem cells that possess superior healing potential
without negative medical or ethical issues.
Since 2011, through our
own research and collaborations with leading academic institutions, we have developed proprietary protocols, built an extensive
intellectual property portfolio, developed complete treatment offerings for erectile dysfunction and are performing ground-breaking
research with our amniotic fluid-based stem cell.
For additional information visit: www.CREATIVEMEDICALTECHNOLOGY.com
Forward-Looking Statements
release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "aim",
"will likely result", "believe", "expect", "anticipate", "estimate", "intend",
' plan", "contemplate", "seek to", "future", "objective", "goal", ' project",
"should" and similar expressions or variations of such expressions. These forward-looking statements reflect the Company's
current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and
estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from
those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company's most recent
Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company
disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the
date of this release.
516-662-9461/andrew@barwicki.com